Taysha Gene Therapies, Inc.
TSHA
$4.06
-$0.37-8.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.99M | 2.30M | 2.02M | 1.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.99M | 2.30M | 2.02M | 1.79M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 1.99M | 2.30M | 2.02M | 1.79M |
| SG&A Expenses | 8.28M | 8.60M | 8.16M | 4.03M | 7.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.02M | 28.74M | 23.72M | 21.95M | 22.85M |
| Operating Income | -34.02M | -26.75M | -21.42M | -19.93M | -21.06M |
| Income Before Tax | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M |
| EBIT | -34.02M | -26.75M | -21.42M | -19.93M | -21.06M |
| EBITDA | -33.74M | -26.48M | -21.14M | -19.63M | -20.77M |
| EPS Basic | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 |
| Normalized Basic EPS | -0.06 | -0.05 | -0.05 | -0.03 | -0.05 |
| EPS Diluted | -0.09 | -0.09 | -0.08 | -0.07 | -0.10 |
| Normalized Diluted EPS | -0.06 | -0.05 | -0.05 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 353.31M | 297.99M | 269.31M | 268.38M | 267.82M |
| Average Diluted Shares Outstanding | 353.31M | 297.99M | 269.31M | 268.38M | 267.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |